SuperworthMannkind profit margin MNKD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2016.
- Net margin, 12 months
- −11.1%
- Operating margin, 12 months
- 2.3%
- Net margin on a year earlier
- −21.9 pts
- Peer median
- 10.9%
Over the twelve months to Jun 30, 2026, Mannkind kept −11.1% of its revenue as net profit, with an operating margin of 2.3% and a gross margin of 87.8%.
The median for 10 large drugmakers of a similar size is 10.9%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 1.7% | 11.1% | 84.9% |
| FY2024 | 9.7% | 25.4% | 73.2% |
| FY2023 | −6.0% | 4.4% | 68.5% |
| FY2022 | −87.6% | −64.3% | 42.4% |
| FY2021 | n/a | −62.3% | 48.5% |
| FY2020 | −87.9% | −73.5% | 62.2% |
| FY2019 | −82.3% | −70.7% | 55.6% |
| FY2018 | n/a | n/a | 26.5% |
| FY2017 | n/a | n/a | −46.7% |
| FY2016 | 71.9% | 38.5% | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −11.1% | −21.9 pts | 2.3% | |
| Q1 FY26 | −6.6% | −16.7 pts | 4.1% | |
| Q4 FY25 | 1.7% | −8.0 pts | 11.1% | |
| Q3 FY25 | 9.3% | +1.2 pts | 23.3% | |
| Q2 FY25 | 10.9% | +6.1 pts | 22.2% | |
| Q1 FY25 | 10.1% | +6.3 pts | 26.3% | |
| Q4 FY24 | 9.7% | +15.7 pts | 25.4% | |
| Q3 FY24 | 8.1% | +25.8 pts | 20.2% | |
| Q2 FY24 | 4.7% | +34.7 pts | 18.6% | |
| Q1 FY24 | 3.8% | +59.2 pts | 14.0% | |
| Q4 FY23 | −6.0% | +81.6 pts | 4.4% | |
| Q3 FY23 | −17.7% | n/a | −6.8% |
Against its peers
Companies in Drug Manufacturers - General nearest Mannkind's size, closest first, today.
| Company | Profit margin |
|---|---|
| MNKDMannkind | −11.1% |
| AMPHAmphastar Pharmaceuticals | 10.8% |
| OMEROmeros | n/m |
| ABUSArbutus Biopharma | 84.2% |
| COLLCollegium Pharmaceutical | 5.9% |
| PCRXPacira BioSciences | 2.0% |
| ANABAnaptysbio | n/m |
| PAHCPhibro Animal Health | 6.6% |
| ANIPANI Pharmaceuticals | 11.1% |
| CRMDCorMedix | 40.5% |
| ZVRAZevra Therapeutics | 42.8% |
| Peer median | 10.9% |
Where Mannkind ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Mannkind
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.